$36.340
+0.011 (+0.03%)收盤時
PCRX 資訊
PCRX 事件
RBC Raises Pacira Price Target to $36.50
RBC Capital raised the firm's price target on Pacira (PCRX) to $36.50 from $25 and keeps a Sector Perform rating on the shares after the company agreed to be acquired by Viatris (VTRS) for $36.50 per share in cash. The firm sees a limited likelihood of a superior bid given the no-shop provision and the compressed tender offer timeline, the analyst tells investors in a research note.
H.C. Wainwright Downgrades Pacira to Neutral with Price Target of $36.50
H.C. Wainwright downgraded Pacira (PCRX) to Neutral from Buy with a price target of $36.50, down from $38. after the company agreed to be acquired by Viatris (VTRS) for $36.50 per share in cash. The firm views the premium paid and cash consideration as a positive outcome for Pacira shareholders amid slower Exparel volume growth and competitive uncertainty.
Truist Downgrades Pacira to Hold with Price Target of $36.50
Truist downgraded Pacira (PCRX) to Hold from Buy with a price target of $36.50, up from $31, after the company agreed to be acquired by Viatris (VTRS) for $36.50 per share in cash. The firm sees a "clean deal structure" and a path for the buyout to close in mid-to-late November.
Major Averages Decline Amid Rising Oil Prices
The major averages closed broadly lower amid a sharp increase in oil prices, elevated Treasury yields and new jitters about AI fueled by a report on OpenAI's revenue growth. Oil spiked after President Donald Trump said he doesn't want to reach an agreement with Iran to end the war, while the U.S. is reportedly preparing strikes in the region ahead of midterm elections in November.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Starbuckshas explored a takeover of Chipotle, FT saysGlobalFoundriesand TSMCreached an agreement to establish a U.S. supply of silicon interposersDevon Energyagreed to sell Eagle Ford assets to Crescent Energyfor $4.2B in cashViatriswill acquire Pacira Biosciencesfor $36.50 per share in cash, or $1.65BA number of big AI-related names, including Microsoft, Oracle, Nvidia, CoreWeave, and Cerebras, moved lower after the Financial Times reported that OpenAI's annualized revenues were closer to $50B at the end of September, well below the $70B figure previously circulated2. WALL STREET CALLS:Palantirupgraded to Buy at Goldman SachsNXP Semiconductorsdowngraded to Neutral at CitiUnityupgraded to Outperform at Raymond JamesCiti downgraded Xeroxto Sell on challenged print marketDeutsche Bank upgraded Chimeto Buy on higher growth profile3. AROUND THE WEB:Disneyspeaking to studios about Imaxcompetitor, Bloomberg saysThe FTC is investigating if Blockviolated consumer protection laws, Bloomberg reportsShell, BP, TotalEnergies, ConocoPhillips, and Chevronhave each recently expressed interest in investing in the Middle East, targeting greater access to the region's oil and gas reserves, FT reportsAmerican Airlineswill begin rolling out SpaceX'sStarlink across its mainline fleet in early 2027, covering more than 1,000 Airbusand Boeingaircraft and expanding on its previously announced plan to equip over 500 Airbus aircraft, Bloomberg saysBroadcomrecently has been working to arrange over $50B in financing for OpenAI's custom AI semiconductor, which the firms are developing together, WSJ says4. MOVERS:Securitizegained after announcing the launch of Securitize StocksAccentureincreased in New York after announcing a major expansion of its collaboration with Dell TechnologiesAngioDynamicsdeclined after reporting Q1 results and providing guidance for FY27Hims & Herswas lower after naming Jon Franklin as Chief Accounting OfficerTilrayfell in New York after reporting Q1 results, with EPS beating consensus5. EARNINGS/GUIDANCE:PepsiCoreported upbeat Q3 results but cut its FY core EPS growth guidanceLevi Straussprovided a "beat and raise" report for Q3Helen of Troyreported Q2 results and raised its outlook for FY27Tomi Environmentalreported preliminary Q3 resultsBeyond Airreported preliminary Q3 results and backed its outlook for FY26INDEXES:The Dow rose 51.77, or 0.10%, to 51,231.64, the Nasdaq lost 345.35, or 1.25%, to 27,193.34, and the S&P 500 declined 36.41, or 0.47%, to 7,765.36.
Oppenheimer Downgrades Pacira to Perform After $36.50 Acquisition by Viatris
Oppenheimer downgraded Pacira (PCRX) to Perform from Outperform after the company agreed to be acquired by Viatris (VTRS) for $36.50 per share in cash.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。